Here are the DEF 14A proxy statements from Liminatus Pharma, Inc. Warrants (LIMNW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LIMNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIMNW filings page.
Liminatus Pharma, Inc. is calling a 2026 annual stockholder meeting on August 3, 2026 to vote on three main items: electing two Class I directors (Nicholas Fernandez and Dr. Ji Yeon Baek), ratifying WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2026, and authorizing the Board to implement a reverse stock split of up to 1-for-50 and related charter amendment to help meet Nasdaq or other exchange listing requirements.
There were 67,160,362 shares of common stock outstanding as of the July 2, 2026 record date, with one vote per share and no cumulative voting. Significant holders include Valetudo Therapeutics LLC at 14.3%, Samda Biolab Co., Ltd. at 5.1%, and Ewon Comfortech Co., Ltd. at 8.2%. The company recently acquired InnocsAI LLC, issuing 11,188,729 common shares and 158,881.1271 shares of Series A Non-Voting Convertible Preferred Stock, each convertible into 10,000 common shares after required stockholder approval. CEO Chris Kim received salary of $183,333 in 2025 and has $0.21 million in deferred compensation accrued.